For Stage IIIC, therapy options include sequential or concurrent ChT and RT, RT alone, new fractionation schedules, radiosensitizers, combined-modality approaches, or targeted drug delivery in patients with EGFR-mutated or ALK-translocated cancers, and adaptive radiation therapy with response monitoring based on positron emission tomography (under clinical evaluation) [81,82,83,84,85]. This evidence concerns the gene EGFR and cancer.